International: +1-347-960-6455
Opioid-Induced Bowel Dysfunction Therapeutics - Pipeline Analysis 2018

Opioid-Induced Bowel Dysfunction Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10032 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Gastroenterology
Select License Type

Opioid-induced bowel dysfunction occurs due to excessive consumption of opioids to manage pain. Opioid is generally use in the clinical management of pain which affects gastrointestinal tract and causes several types of side-effects. Opioid induced constipation is the most common side-effect occur due to excessive usage of opioids. People using opioid generally suffer from delayed gastric emptying, dyspepsia, nausea and vomiting. The opioids act on μ, δ, and κ-opioid receptors and perform function with respect to the type of receptors. The μ and δ opioid receptors are targeted for analgesic function. The κ-opioid receptor targets to analgesic, hallucinogenic, anti-depressants, and anti-anxiety functions. Some of the major companies involved in the development of therapeutic agents for the treatment of opioid-induced bowel dysfunction includes Synergy Pharmaceuticals Inc., and Theravance Biopharma Inc.

Theravance Biopharma Inc. is involved in developing TD-1211, a μ-opioid receptor antagonist, for the treatment of opioid-induced bowel syndrome. Moreover, Synergy Pharmaceuticals Inc. is currently involved in development of SP-333, a guanylate cyclase C agonist, for the management of this medical condition.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.